Maximal tumor removal for prostate cancer that has spread a little
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of surgery and radiation to remove as much cancer as possible in men with prostate cancer that has spread to a few spots outside the prostate. It aims to see if this aggressive approach can improve long-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 75 years old.
- You have prostate cancer that has spread to only a few places in the body (oligometastatic).
- You are healthy enough to have both radiation and prostate surgery.
- Your doctor expects you to live at least 10 more years.
- You agree to join the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the drug rezvilutamide to standard hormone therapy, along with prostate removal surgery and precise radiation to cancer spots, helps men whose prostate cancer has spread to a limited number of places (no more than 10 spots, and not in organs like the liver or lungs).
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
This trial tests whether giving radiotherapy to the prostate and a few cancer spots elsewhere in the body can help control low-spread prostate cancer. It is for people who have not had any previous prostate cancer treatment.
This Phase 2 trial studies whether removing the prostate (cytoreductive radical prostatectomy) and targeting visible metastases with radiation can improve outcomes for men with newly diagnosed metastatic prostate cancer who are already starting apalutamide plus hormone therapy (ADT). It’s meant to see if treating “visible spots” after the initial medication helps the cancer control last longer.
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
Hear when a new Oligometastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.